{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04372277",
            "orgStudyIdInfo": {
                "id": "PTC06"
            },
            "organization": {
                "fullName": "Psoriasis Treatment Center of Central New Jersey",
                "class": "OTHER"
            },
            "briefTitle": "Taltz in Combination With Enstilar for Psoriasis",
            "officialTitle": "Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "taltz-in-combination-with-enstilar-for-psoriasis"
        },
        "statusModule": {
            "statusVerifiedDate": "2020-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-04-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2021-03-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2021-03-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-04-29",
            "studyFirstSubmitQcDate": "2020-04-29",
            "studyFirstPostDateStruct": {
                "date": "2020-05-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2020-04-29",
            "lastUpdatePostDateStruct": {
                "date": "2020-05-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Psoriasis Treatment Center of Central New Jersey",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eli Lilly and Company",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "Enstilar in combination with Taltz for plaque psoriasis.",
            "detailedDescription": "A single center study of 25 subjects to assess the addition of Enstilar Foam in patients receiving Taltz for \u2265 24 weeks with BSA between 3% and 8%."
        },
        "conditionsModule": {
            "conditions": [
                "Psoriasis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "open-label",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Enstilar",
                    "type": "EXPERIMENTAL",
                    "description": "Enstilar foam",
                    "interventionNames": [
                        "Drug: Enstilar"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Enstilar",
                    "description": "topical Enstilar foam",
                    "armGroupLabels": [
                        "Enstilar"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Body Surface Area 0 or 1",
                    "description": "Body surface area where 1 palm is equivalent to 1%. Endpoint will evaluate number of patiens who achieve body surface are 0 or 1.",
                    "timeFrame": "4 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adult \u2265 18 years of age;\n* Diagnosis of chronic plaque-type\n* Body Surface Area between 3%-8%.\n* Patient has been treated with Taltz for a minimum of 24 weeks\n* Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.\n* Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination\n* Able and willing to give written informed consent prior to performance of any study-related procedures.\n\nExclusion Criteria\n\n-\u02c23% or \\>8% BSA\n\n* Patient not receiving Taltz, or receiving Taltz \\<24 weeks\n* Any condition, which would place the subject at unacceptable risk if he/she were to participate in the study.\n* Pregnant or breast feeding, or considering becoming pregnant during the study.\n* Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).\n* Use of oral systemic medications for the treatment of psoriasis within 4 weeks.\n* Patient used other topical therapies to treat within 2 weeks of the Baseline Visit.\n* Patient received UVB phototherapy within 2 weeks of Baseline.\n* Patient received PUVA phototherapy within 4 weeks of Baseline.\n* Patient has a known hypersensitivity to the excipients of Enstilar\u00ae as stated in the label.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jerry Bagel, MD",
                    "role": "CONTACT",
                    "phone": "6094434500",
                    "email": "dreamacres1@aol.com"
                },
                {
                    "name": "Elise Nelson",
                    "role": "CONTACT",
                    "phone": "6094434500",
                    "email": "enelson@windsordermatology.com"
                }
            ],
            "locations": [
                {
                    "facility": "Psoriasis Treatment Center of Central New Jersey",
                    "status": "RECRUITING",
                    "city": "East Windsor",
                    "state": "New Jersey",
                    "zip": "08520",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elise Nelson",
                            "role": "CONTACT",
                            "phone": "609-443-4500",
                            "email": "enelson@windsordermatology.com"
                        },
                        {
                            "name": "Jerry Bagel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "David Nieves, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Wendy Myers, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Alexa Hetzel, PA-C",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Brianna Butler, PA-C",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.268,
                        "lon": -74.54043
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "submissionTracking": {
                "estimatedResultsFirstSubmitDate": "2024-03-14",
                "submissionInfos": [
                    {
                        "releaseDate": "2024-03-14",
                        "resetDate": "2024-04-10",
                        "mcpReleaseN": 1
                    }
                ]
            }
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011565",
                    "term": "Psoriasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017444",
                    "term": "Skin Diseases, Papulosquamous"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14422",
                    "name": "Psoriasis",
                    "asFound": "Psoriasis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19713",
                    "name": "Skin Diseases, Papulosquamous",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4909",
                    "name": "Betamethasone",
                    "relevance": "LOW"
                },
                {
                    "id": "M4910",
                    "name": "Betamethasone Valerate",
                    "relevance": "LOW"
                },
                {
                    "id": "M229285",
                    "name": "Betamethasone-17,21-dipropionate",
                    "relevance": "LOW"
                },
                {
                    "id": "M259190",
                    "name": "Betamethasone benzoate",
                    "relevance": "LOW"
                },
                {
                    "id": "M248787",
                    "name": "Betamethasone sodium phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M350710",
                    "name": "Calcipotriene",
                    "relevance": "LOW"
                },
                {
                    "id": "M344737",
                    "name": "Ixekizumab",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                }
            ]
        }
    },
    "hasResults": false
}